Abstract
Future advances in the pharmacotherapy of lung disease will occur mainly in the treatment of asthma, and will include the development of new long-actingβ 2-agonists, long-acting parasympatholytics, phosphodiesterase inhibitors, corticosteroids with fewer systemic side-effects, and other antiinflammatory drugs. Free radicals play an important role in most lung diseases, including asthma, emphysema, fibrosis, and adult respiratory distress syndrome. The search for free radical scavengers is now in progress. Replacement therapy with α1-antitrypsin and surfactant is now possible. Progress in this area stems principally from a better understanding of the pathogenesis of lung disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rees J.β 2 Agonists and asthma. BMJ 1991;302:1166–7.
Van Schayck CP. Treatment of asthma and chronic bronchitis in patients from general practice [dissertation]. Nijmegen: Univ of Nijmegen, 1990.
Bown W. Warning letter links asthma death to drugs. New Scientist 1991;27 July.
Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanisms byβ 2-agonists. Lancet 1991;337:717–9.
Lofdahl CG. Basic pharmacology of new long-acting sympathomimetics. Lung 1990;168 Suppl:18–21.
Johnson M. The pharmacology of salmeterol. Lung 1990;168 Suppl:115–9.
Schroeckenstein DC, Bush RK, Chervinsky P, Busse WW. Twelve hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol 1988;82:115–9.
Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991;46:160–4.
Harding SM, Daniel MJ. The clinical pharmacology of inhaled fluticasone [abstract]. SEP-SEPCR Symposium; London, 12 Sept 1990.
Beume R, Schudt CH, Riedel R, Kilian U. Zardaverine — a new bronchodilator with anti-allergic and antiinflammatory activity? Eur Respir J 1989;2 Suppl 5:3993.
Kroegel C. The role of eosinophils in asthma. Lung 1990;168 Suppl:5–17.
Kurihara K, Wardlaw AJ, Moqbel R, Kay AB. Inhibition of platelet activating fator, PAF-induced chemotaxis and PAF-binding to human eosinophils and neutrophils by a specific ginkgolide-derived PAF antagonist BN 52021. J Allergy Clin Immunol 1989;83:82–90.
Doelman CJA, Bast A. Oxygen radicals in lung pathology. Free Radical Biol Med 1990;9:381–400.
Thomas DA, Myers MA, Wiecert B, Schreier H, Gonzales Rothi RJ. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 1991;99:1269–70.
Carell RW. The molecular structure and pathology of alpha 1 antitrypsin. Lung 1990;169 Suppl:530–4.
Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1 antitrypsin deficiency by the aerosol route. Lung 1990;169 Suppl:565–8.
McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1 antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392–4.
Schafer KP, Voss T, Melchers K, Eistetter H. Lung surfactant: a biotechnological challenge. Lung 1990;168 Suppl:851–9.
Speer CP, Harms K, Herting E, et al. Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung 1990;168 Suppl:870–6.
Seeger W, Pison U, Buchhorn R, et al. Surfactant abonormalities and adult respiratory failure. Lung 1990;168 Suppl:891–902.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van der Kuy, A. Future developments in the pharmacotherapy of lung disease. Pharmaceutisch Weekblad Scientific Edition 14, 221–223 (1992). https://doi.org/10.1007/BF01962543
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01962543